PLEKHH2: A Potential Drug Target and Biomarker (G130271)

Target Name: PLEKHH2

NCBI ID: G130271

Other Name(s): pleckstrin homology domain containing, family H (with MyTH4 domain) member 2 | PLEKHH1L | PKHH2_HUMAN | Pleckstrin homology domain-containing family H member 2 | KIAA2028 | Pleckstrin homology, MyTH4 and FERM domain containing H2 | pleckstrin homology, MyTH4 and FERM domain containing H2

PLEKHH2: A Potential Drug Target and Biomarker

Pleckstrin homology domain containing, family H (with MyTH4 domain) member 2 (PLEKHH2) is a protein that has been identified as a potential drug target and biomarker. This protein is a key component of the endoplasmic reticulum, where it plays a role in the transport of various proteins to and from the cytoplasm. PLEKHH2 has been shown to be involved in the regulation of cellular processes such as cell signaling, DNA replication, and metabolism.

The discovery of PLEKHH2 as a potential drug target comes from a study by the research group of Dr. Qun Liu at the University of California, San Diego. This study identified PLEKHH2 as a protein that was overexpressed in various cancer cell types, including breast, ovarian, and colorectal cancers. The researchers then used small interfering RNA (siRNA) screening to determine that PLEKHH2 was involved in the regulation of the cell cycle and the apoptosis (programmed cell death) pathway.

Furthermore, the study showed that PLEKHH2 was positively correlated with the expression level of the drug resistance gene, Taranine (TN), in various cancer cell types. This suggests that PLEKHH2 may play a role in the development and progression of cancer, particularly in those that are resistant to traditional cancer treatments.

The potential implications of PLEKHH2 as a drug target are significant. If PLEKHH2 is found to be involved in the regulation of the cell cycle and apoptosis, it may be a potential target for small molecules or other therapeutic agents that can inhibit these processes. This could lead to the development of new treatments for various types of cancer.

Additionally, the discovery of PLEKHH2 as a biomarker for cancer has significant implications for the early detection and diagnosis of cancer. PLEKHH2 is expressed in various cell types and has been shown to be involved in the regulation of cellular processes that are important for the development and progression of cancer. Therefore, it may be a potential biomarker for cancer, particularly in the early stages of disease.

In conclusion, PLEKHH2 is a protein that has been identified as a potential drug target and biomarker for cancer. The discovery of its involvement in the regulation of the cell cycle and apoptosis pathway, as well as its positive correlation with the expression level of the drug resistance gene, Taranin, suggests that it may be a promising target for small molecules or other therapeutic agents that can inhibit these processes. Further research is needed to determine the full implications of PLEKHH2 as a potential drug target and biomarker for cancer.

Protein Name: Pleckstrin Homology, MyTH4 And FERM Domain Containing H2

Functions: In the kidney glomerulus may play a role in linking podocyte foot processes to the glomerular basement membrane. May be involved in stabilization of F-actin by attenuating its depolymerization. Can recruit TGFB1I1 from focal adhesions to podocyte lamellipodia

More Common Targets